SCHEMBL1074499

SCHEMBL1074499

CCCCCNS(=O)(=O)c1ccc(Oc2ccc(N)c(C(=O)OC)c2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.52
PKM P14618 1/20 0.49
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
MAPK1 P28482 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MMP2 P08253 6/20 0.45
CA12 O43570 5/20 0.45
CA1 P00915 5/20 0.45
CA2 P00918 5/20 0.45
CA9 Q16790 5/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 2/20 0.43
TSHR P16473 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1466023 0.91 LMNA (0.45) ALDH1A1PKMLMNAHTTMAPK1
SCHEMBL1465465 0.90 ALDH1A1 (0.50) ALDH1A1PKMLMNAHTTMAPK1
SCHEMBL1082241 0.84 ALDH1A1 (0.49) ALDH1A1PKMLMNAHTTMAPK1
SCHEMBL1465590 0.83 LMNA (0.41) ALDH1A1LMNAHTTMAPK1KMT2A
SCHEMBL1074406 0.82 KDM4E (0.46) ALDH1A1HSD17B10TSHRKDM4EGAA
SCHEMBL1659490 0.81 ALDH1A1 (0.50) ALDH1A1LMNAHTTMEN1KMT2A
SCHEMBL3511250 0.81 KDM4E (0.45) ALDH1A1HSD17B10TSHRKDM4EGAA
SCHEMBL1467336 0.77 LMNA (0.44) ALDH1A1PKMLMNAHTTMAPK1
SCHEMBL1465587 0.77 TDP1 (0.46) ALDH1A1PKMLMNAHTTMAPK1
SCHEMBL1465840 0.77 ALDH1A1 (0.41) ALDH1A1MMP2HSD17B10TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071197-A1 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS BIOLIPOX AB (LV) 2011-03-24 US disclosed
EP-2274280-A2 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS Biolipox AB (SE) 2011-01-19 EP disclosed
WO-2009127822-A2 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS BIOLIPOX AB (SE) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071197-A1 BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS LTC4S, LTB4R2, LTB4R ALDH1A1 474/4885PKM 2760/4885LMNA 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.